<DOC>
	<DOCNO>NCT00649545</DOCNO>
	<brief_summary>The primary objective study assess safety ( collect adverse event serious adverse event ) adalimumab administer every week patient moderately severly active rheumatoid arthritis fail prior disease-modifying anti-rheumatic drug ( DMARDs ) .</brief_summary>
	<brief_title>Study Human Anti-TNF Monoclonal Antibody Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patient complete ( i.e . drop ) DE013 study fulfills criteria 212 Patients 18 year age old Female either childbearing , define postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential , practice acceptable method birth control Female childbearing potential must negative serum pregnancy test prior first dose adalimumab Diagnosis active RA define &gt; = 5 swollen joint one following : Positive RF One joint erosion present xray HAQ score &gt; 1 Patient fail 2 biologics Patient previous treatment cyclophosphamide chlorambucil Previous treatment total lymphoid irradiation antiCD4 CAMPATH 1H monoclonal antibody result presistent CD4 lymphopenia ( CD4 lymphocytes + &lt; 500/mm3 ) History cancer within past 10 year unless successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma and/or localize carcinoma situ cervix History malignant lymphoma leukemia regardless treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>